Effect of SGN-CD33A and SGD-1882 on cell cycle in HEL 92.1.7 cells
Treatment and concentration . | % in phase of cell cycle . | ||
---|---|---|---|
G1 . | S . | G2-M . | |
Untreated | 50 | 32 | 12 |
0 | |||
Nonbinding ADC (ng/mL) | |||
100 | 50 | 35 | 11 |
SGN-CD33A (ng/mL) | |||
1 | 44 | 36 | 17 |
10 | 26 | 36 | 34 |
100 | 10 | 22 | 57 |
SGD-1882 (nM) | |||
0.01 | 45 | 36 | 15 |
0.1 | 26 | 41 | 29 |
1 | 5 | 8 | 73 |
Treatment and concentration . | % in phase of cell cycle . | ||
---|---|---|---|
G1 . | S . | G2-M . | |
Untreated | 50 | 32 | 12 |
0 | |||
Nonbinding ADC (ng/mL) | |||
100 | 50 | 35 | 11 |
SGN-CD33A (ng/mL) | |||
1 | 44 | 36 | 17 |
10 | 26 | 36 | 34 |
100 | 10 | 22 | 57 |
SGD-1882 (nM) | |||
0.01 | 45 | 36 | 15 |
0.1 | 26 | 41 | 29 |
1 | 5 | 8 | 73 |
HEL 92.1.7 cells were incubated with SGN-CD33A, SGD-1882, or a nonbinding control ADC for 48 hours before BrdU incorporation and processing for flow cytometric analysis. The results shown are representative of data obtained from 3 separate experiments. Nascent DNA synthesis was detected with anti-BrdU, whereas total DNA content was determined with propidium iodide. One hundred nanograms per milliliter SGN-CD33A is the ADC equivalent of 1 nM SGD-1882.